pirfenidone has been researched along with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, Z; Cheng, Z; Hu, G; Jiang, D; Li, Q; Lu, M; Peng, Z; Tao, L; Xiong, X | 1 |
| Jiang, Y; Li, N; Li, X; Liang, J; Wang, N; Yang, C; Yang, G; Zhang, K; Zhou, H | 1 |
2 other study(ies) available for pirfenidone and 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
| Article | Year |
|---|---|
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Discovery; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Mice; Molecular Structure; NIH 3T3 Cells; Oxidative Stress; Piperazines; Pyridones; Rats; Structure-Activity Relationship | 2018 |
Discovery of a novel Pleuromutilin derivative as anti-IPF lead compound via high-throughput assay.
Topics: Animals; Bleomycin; Diterpenes; Fibroblasts; High-Throughput Screening Assays; Idiopathic Pulmonary Fibrosis; Lung; Mice; Mice, Inbred C57BL; NIH 3T3 Cells; Pleuromutilins; Polycyclic Compounds; Transforming Growth Factor beta1 | 2022 |